ImmunityBio Net Income

The latest net income for IBRX is $-990M as of June 2026. That compares with $-370M in the prior-year period — down 170.3% year over year. That is below the Healthcare sector average of $17B. Investors often review this figure alongside ImmunityBio's historical trend and sector peers before judging valuation or financial health.

Over the past year, IBRX's net income moved from $-370M to $-990M — a 170.3% year-over-year decrease. If the trend continues in the same direction for several quarters, it can signal a meaningful shift in ImmunityBio's operating scale or balance-sheet position.

Against Healthcare companies, IBRX currently prints $-990M for net income, while the sector average sits near $17B. That is roughly 106.0% below the sector mean. Large gaps often invite a closer look at ImmunityBio's growth, margins, and balance sheet.

A net income figure of $-990M for IBRX is a snapshot of scale on that line item. On its own it does not say whether the business is healthy — you also want growth rate, margins, and how the number compares with similar companies. The Healthcare average is about $17B. Explore the charts below for those layers of context.

After noting IBRX's net income ($-990M), review year-over-year change from $-370M, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.